Top 10 Countries in Global Innovation Index 2014

The Global Innovation Index 2014 report by Soumitra Dutta, Bruno Lanvin, and Sacha Wunsch-Vincent – co-published by Cornell University, INSEAD and WIPO is out.

This report assessed 143 economies using 83 different indicators. Based on Innovation Performance, Global Innovation Index published World’s Top 10 countries which include – Switzerland (1st), United Kingdom, Sweden, Finland, Netherlands, US, Singapore, Denmark, Luxembourg, Hong Kong.

The table below shows the leading countries in the Global Innovation Index 2014.


Source: Global Innovation Index 2014 Report.


Why Intellectual Property Protection is Vital in BioPharMed Industry?

In a recent article, – described that Intellectual Property Protections are vital for Biopharmaceutical Industry. Why is it so critical? There are several reasons for this:

1) Strategic Investments that go into R&D
2) Of the thousands of experiments done, only a handful have positive outcomes and make it to FDA for approval
3) Very few drugs get approved by FDA
4) It takes 7 to 10 years to make it from R&D to Market (after FDA approval) and as per a study, it costs about $1.2 billion.


Yes – discovering life changing, life saving drugs is not easy. Odds are high and there are challenges that need to be tackled. Then what is the motivator? – Providing new cure and making a windfall.

Due to these reasons and more, it is imperative to have sound IP Strategy creating strong IP Creation and IP Protection including the enforcement tools to defend against infringing patents. Also, strong IP Protection ensures recouping the substantial investments in new drug development (NDA or BLA applications).

US FTC, EU and China probe Qualcomm on breach of Competition Rules

Qualcomm in its Annual report, disclosed EU and US FTC investigations on its breach of competition rules. According to the report, Qualcomm is ready, if violation is found, on broad range of remedies including possible imposition of fine and/or injunction relief and restriction of certain business practices. EU is probing Qualcomm to see if entered into anti-competitive agreements or has abused dominant market position.


US Federal Trade Commission (FTC) is investigating whether Qualcomm’s patent licensing arrangements are anti-competitive or not. Under the scanner is the issue as to whether Qualcomm failed to ensure others could license their patents on Fair, Reasonable and Non-discriminatory (FRAND) terms.

China, also is probing Qualcomm to ascertain if it breached Chinese anti-monoply laws. If National Development and Reform Commission (NDRC) finds breach, then it could potentially impose 10 percent of Qualcomm’s annual revenues.

For more details, refer to the Annual report.